ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 14

Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

February 21, 2025

Andrew Kuykendall, MD, Naseema Gangat, MBBS , Claire Harrison, MD, FRCP, FRCPath , Raajit K. Rampal, MD, PhD, Pankit Vachhani, MD

Panelists discuss the types of questions that real-world (RW) data can answer in comparison to with clinical trial data, and how it they can complement clinical findings in treatment decision-making.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Initial Treatment Strategies for Polycythemia Vera

EP. 2: Cytoreductive Therapy in PV Treatment Paradigm

EP. 3: JAK Inhibition in Polycythemia Vera: Treatment Updates

EP. 4: Interferon Therapy in PV

EP. 5: Safety Considerations for PV Therapy

EP. 6: Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

EP. 7: Interferon Real- World Treatment Patterns in PV

EP. 8: Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks

EP. 9: Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024

EP. 10: An Overview to Myelofibrosis and Disease Risk

EP. 11: Treatment Goals for Myelofibrosis

EP. 12: Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials

EP. 13: Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib

Now Viewing

EP. 14: Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice

EP. 15: Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches

EP. 16: Myelofibrosis at ASH 2024: Key Updates and Emerging Therapies

EP. 17: MPN Milestones of 2024 and What’s Next for 2025

Video content above is prompted by the following:

In comparison with clinical data, what questions can RW data answer?